thrombosis

bvs

Bioresorbable Scaffolds: Promising in Peripheral Territory

Bioresorbable Vascular Scaffolds (BVS) could change the paradigm of peripheral angioplasty according to several small studies suggesting these everolimus eluting devices could significantly improve symptoms in patients with intermittent claudication. &nbsp; [plain] Three year outcomes of the ESPRIT I trial, presented at VIVA 2016 (held in Las Vegas) showed there were no new events between<a href="https://solaci.org/en/2016/10/11/bioresorbable-scaffolds-promising-in-peripheral-territory/" title="Read more" >...</a>

bifurcaciones tap o culotte provisional stenting

Culotte vs. TAP in Bifurcations: Which is Better?

Courtesy of Dr. Agustín Vecchia. &nbsp; In treating bifurcations, the provisional stenting strategy continues to be preferred. However, a percentage of these lesions must be treated with two stents, which involves different techniques. In provisional stenting, when two stents are required, a recent consensus document of the European Bifurcation Club has recently recommended the TAP<a href="https://solaci.org/en/2016/09/14/culotte-vs-tap-in-bifurcations-which-is-better/" title="Read more" >...</a>

doble antiagregacion plaquetaria sexo

Dual Antiplatelet Therapy in Men and Women: Are There Differences?

Courtesy of Dr. Agustín Vecchia. &nbsp; Currently, the duration of dual antiplatelet therapy (DAPT) after stent placement is one of the most highly debated topics in Cardiology. On the one hand, women are usually underrepresented in trials in our specialty; on the other, the fact that symptoms of coronary disease are different in women is well-known. &nbsp; The aim<a href="https://solaci.org/en/2016/09/12/dual-antiplatelet-therapy-in-men-and-women-are-there-differences/" title="Read more" >...</a>

stents liberadores de farmacos

Xience V: Safe in “Real-Life” Bifurcation Lesions

Courtesy of Dr. Rodrigo Abreu. &nbsp; INTRODUCTION Bifurcation lesion treatment has evolved considerably in the last years: from balloon angioplasty (with high occlusion and restenosis rates) to bare metal stent angioplasty (with a procedural success around 86% and major adverse cardiac events [MACE] at 1 year around 32%). The subsequent emergence of drug-eluting stents (DES) reduced<a href="https://solaci.org/en/2016/09/09/xience-v-safe-in-real-life-bifurcation-lesions/" title="Read more" >...</a>

Current Bare-Metal Stents: Similar to DES in the Very Long-Term

The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal infarction between current conventional stents and drug-eluting stents at over 5 years in patients with stable or unstable coronary disease. As expected, NORSTENT did find a difference in revascularization rates between both groups. &nbsp; This study presented at the<a href="https://solaci.org/en/2016/09/07/current-bare-metal-stents-similar-to-des-in-the-very-long-term/" title="Read more" >...</a>

Primary PCI: Similar Results During Day and Night

Patients with ST-segment elevation myocardial infarction included in the CHAMPION PHOENIX trial admitted during nights, weekends, and holidays presented the same prognosis and good clinical outcomes as those who were admitted during regular daytime hours. &nbsp; Prior studies had indicated that off-hours admission was associated with worse outcomes; however, this particular analysis contradicts such a<a href="https://solaci.org/en/2016/09/07/primary-pci-similar-results-during-day-and-night/" title="Read more" >...</a>

terapia antitrombótica triple

Anticoagulation and PCI: How Long Should Triple Therapy Last?

The aim of this study was to compare clinical outcomes in relation to the duration of triple antithrombotic therapy in patients with indications for oral anticoagulation undergoing coronary angioplasty. The optimal period for the prescription of these three drugs has not been studied. &nbsp; Between 2009 and 2013, 8772 consecutive patients undergoing coronary angioplasty were included<a href="https://solaci.org/en/2016/08/30/anticoagulation-and-pci-how-long-should-triple-therapy-last/" title="Read more" >...</a>

abciximab diabéticos

Intracoronary Abciximab reduces events in diabetics during PPCI

Diabetic patients have an increased risk of future cardiovascular events after an ST elevation MI. Administration of an intracoronary abciximab bolus during primary PCI could be beneficial for this high risk subgroup of patients. &nbsp; This study reports one year clinical outcomes and CMR imaging of patients randomized to intracoronary vs. intravenous abciximab during primary<a href="https://solaci.org/en/2016/08/24/intracoronary-abciximab-reduces-events-in-diabetics-during-ppci/" title="Read more" >...</a>

absorv abbott a largo plazo

ABSORV at Long Term in Daily Practice Lesions

This work reports one year outcomes of the BVS Expand registry. Multiple studies have shown the safety and feasibility of the everolimus eluting bioresorbable scaffold ABSORB (Abbott Vascular, Santa Clara, California), but medium and long term data are limited and only on simple lesions. &nbsp; This is a prospective single-center registry assessing ABSORB performance in<a href="https://solaci.org/en/2016/08/24/absorv-at-long-term-in-daily-practice-lesions/" title="Read more" >...</a>

cangrelor vs. clopidogrel infartos peri-procedimiento

Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that have not previously received any other P2Y12 inhibitor. &nbsp; The CHAMPION PHOENIX trial randomized a total of 11,145 patients to cangrelor vs. clopidogrel. &nbsp; The study sought to explore the effect of cangrelor on peri-procedural acute myocardial infarction<a href="https://solaci.org/en/2016/08/22/peri-procedural-mi-reduction-cangrelor-or-clopidogrel/" title="Read more" >...</a>

Top